A Novel Drug Delivery Carrier Based on α-eleostearic Acid Grafted Hydroxyapatite Composite

The purpose of this study is to explore and develop a novel biocompatibility drug delivery carrier for controllingontrolled drug release. The α-eleostearic acid grafted hydroxyapatite (α-ESA-g-HA) composite was synthesized by using silane coupling agent and characterized by Fourier Transformation Infrared Spectroscopy (FT-IR), Thermal Gravimetric Analysis (TGA) and Scanning Electron Microscope (SEM), respectively. The in vitro drug loading and controlled release behaviors of α-ESA-g-HA composite were investigated using ciprofloxacin as the model drug. The amount of ciprofloxacin loading and released was calculated by absorbance value which was determined by UV-Vis spectrophotometry at wavelength of 277 nm. The biocompatibility of α-ESA-g-HA composite was assessed by 3-(4,5)-dimethylthiahiazo(-z-yl)-3,5-di-phenytetrazoliumromide(MTT) assay, nuclear morphology and platelet adhesion. The results showed that the α-ESA-g-HA had nontoxic and good biocompatibility. According to the results mentioned above, the α-ESA-g-HA is an effective drug delivery carrier, which could increase drug loading capacity and control drug release, so further studies are necessary to evaluate clinical application and human health care.